Bafna Pharmaceuticals Share Price
296.00-5.85 (-1.94%)
+187.46% past 1 Year
Bafna Pharmaceuticals is engaged in the manufacturing of pharmaceutical products. The company exports its products to the United Kingdom, Australia, Sri Lanka, Africa, Philippines, Tanzania, Nigeria, and Commonwealth countries. Additionally,
Corporate filings & documents
Announcements
We herewith enclose the Newspaper Publication for the 31st Annual General Meeting of the Company published in Business Standard and Makkal Kural on August 20 2026.
1 week agoWe herewith enclose the Newspaper Publication for the 31st Annual General Meeting of the Company published in Business Standard and Makkal Kural on August 20 2026.
1 week agoWe herewith enclose the Notice of 31st Annual General Meeting of the Company scheduled to be held on Friday September 11 2026 at 10.00 A.M along with the Annual Report of the Company for the FY 2025-2026.
2 weeks agoWe herewith enclose the Notice of 31st Annual General Meeting of the Company scheduled to be held on Friday September 11 2026 at 10.00 A.M along with the Annual Report of the Company for the FY 2025-2026.
2 weeks agoWe herewith enclose the Annual Report of the Company for the F.Y 2025-2026.
2 weeks agoWe herewith enclose the Annual Report of the Company for the F.Y 2025-2026.
2 weeks agoNewspaper Publication for the Unaudited Financial Results of the Company for the Quarter ended June 30 2026 as published in Business Standard and Makkal Kural on August 13 2026.
2 weeks agoNewspaper Publication for the Unaudited Financial Results of the Company for the Quarter ended June 30 2026 as published in Business Standard and Makkal Kural on August 13 2026.
2 weeks agoWe herewith enclose the intimation for Book Closure and Cut-Off dates for the purpose of 31st Annual General Meeting of the Company.
3 weeks agoWe herewith enclose the intimation for Book Closure and Cut-Off dates for the purpose of 31st Annual General Meeting of the Company.
3 weeks agoWe hereby inform that the 31st Annual General Meeting (AGM) of the Company is scheduled to be held on Friday September 11 2026 at 10.00 A.M through Video Conferencing (VC) / Other Audio Visual Means (OAVM).
3 weeks agoWe hereby inform that the 31st Annual General Meeting (AGM) of the Company is scheduled to be held on Friday September 11 2026 at 10.00 A.M through Video Conferencing (VC) / Other Audio Visual Means (OAVM).
3 weeks agoWe herewith enclose the Unaudited Financial Results for the Quarter ended June 30 2026 as approved by the Board of Directors in its meeting held on August 11 2026.
3 weeks agoWe herewith enclose the Unaudited Financial Results for the Quarter ended June 30 2026 as approved by the Board of Directors in its meeting held on August 11 2026.
3 weeks agoWe hereby inform you that the Board of Directors in their meeting held on August 11 2026 inter-alia considered and approved i) Unaudited Financial Results of the Company for the Quarter ended June 30 2026 along with the Limited Review Report; ii) Fixed the date of 31st Annual General Meeting (AGM) of the Company Book Closure Date and Cut-Off Date for the purpose of AGM.
3 weeks agoWe hereby inform you that the Board of Directors in their meeting held on August 11 2026 inter-alia considered and approved i) Unaudited Financial Results of the Company for the Quarter ended June 30 2026 along with the Limited Review Report; ii) Fixed the date of 31st Annual General Meeting (AGM) of the Company Book Closure Date and Cut-Off Date for the purpose of AGM.
3 weeks agoBafna Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2026 inter alia to consider and approve the Un-Audited Financial Results for the Quarter ended June 30 2026
4 weeks agoBafna Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2026 inter alia to consider and approve the Un-Audited Financial Results for the Quarter ended June 30 2026
4 weeks agoCertificate under Regulation 74(5) of SEBI (DP) Regulations 2018 for the quarter ended June 30 2026.
1 month agoCertificate under Regulation 74(5) of SEBI (DP) Regulations 2018 for the quarter ended June 30 2026.
1 month agoIntimation for Closure of Trading Window
2 months agoIntimation for Closure of Trading Window
2 months agoIntimation for retirement of Mr. Navin Kumar (DIN: 08778662) as an Independent Director of the Company upon completion of his first term with effect from close of business hours on June 22 2026.
2 months agoIntimation for retirement of Mr. Navin Kumar (DIN: 08778662) as an Independent Director of the Company upon completion of his first term with effect from close of business hours on June 22 2026.
2 months agoIntimation for retirement of Mr. Navin Kumar (DIN: 08778662) as an Independent Director of the Company upon completion of his first term with effect from close of business hours on June 22 2026.
2 months agoIntimation for retirement of Mr. Navin Kumar (DIN: 08778662) as an Independent Director of the Company upon completion of his first term with effect from close of business hours on June 22 2026.
2 months agoNewspaper Publication for the Audited Financial Results of the Company for the Quarter & Year ended March 31 2026 as published in "Financial Express" and "Makkal Kural" on May 31 2026.
3 months agoWe herewith enclose the Audited Financial Results of the Company along with the Statutory Auditors Report for the Quarter and Year ended March 31 2026 as approved by the Board of Directors of the Company at its meeting held on May 29 2026.
3 months agoWe herewith enclose the Audited Financial Results of the Company along with the Statutory Auditors Report for the Quarter and Year ended March 31 2026 as approved by the Board of Directors of the Company at its meeting held on May 29 2026.
3 months agoWe hereby inform you that the Board of Directors in their meeting held on May 29 2026 inter-alia considered and approved the Audited Financial Results of the Company along with the Auditors Report issued by the Statutory Auditors of the Company for the Quarter and Year ended March 31 2026.
3 months agoWe hereby inform you that the Board of Directors in their meeting held on May 29 2026 inter-alia considered and approved the Audited Financial Results of the Company along with the Auditors Report issued by the Statutory Auditors of the Company for the Quarter and Year ended March 31 2026.
3 months agoBafna Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 inter alia to consider and approve the Audited Financial Results for the Quarter and Year ended March 31 2026.
3 months agoWe hereby submit our response to the Clarification sought by the Stock Exchange regarding the movement in the Share Price of the Company.
4 months agoThe Exchange has sought clarification from Bafna Pharmaceuticals Ltd on April 13 2026 with reference to significant movement in price in order to ensure that investors have latest relevant information about the company and to inform the market so that the interest of the investors is safeguarded.<BR><BR>The reply is awaited.
4 months agoCertificate under Regulation 74(5) of SEBi (DP) Regulations 2018 for the Quarter ended March 31 2026.
4 months agoCertificate under Regulation 74(5) of SEBi (DP) Regulations 2018 for the Quarter ended March 31 2026.
4 months agoThe Board of Directors of the Company in the Meeting held on March 27 2026 has inter-alia considered and approved: (i) The appointment of M/s. K. S. Rao & Co. Chartered Accountants Chennai as the Internal Auditor of the Company for the Financial Year 2026-2027; (ii) The appointment of M/s. N. Sivashankaran & Co. Cost Accountants Chennai as the Cost Auditor of the Company for the Financial Year 2026-2027.
5 months agoThe Board of Directors of the Company in the Meeting held on March 27 2026 has inter-alia considered and approved: (i) The appointment of M/s. K. S. Rao & Co. Chartered Accountants Chennai as the Internal Auditor of the Company for the Financial Year 2026-2027; (ii) The appointment of M/s. N. Sivashankaran & Co. Cost Accountants Chennai as the Cost Auditor of the Company for the Financial Year 2026-2027.
5 months agoIntimation for Closure of Trading Window.
5 months agoWe hereby submit our response to the clarification sought by the Stock Exchange regarding the movement in the share price of the Company.
5 months agoWe hereby submit our response to the clarification sought by the Stock Exchange regarding the movement in the share price of the Company.
5 months agoThe Exchange has sought clarification from Bafna Pharmaceuticals Ltd on March 23 2026 with reference to significant movement in price in order to ensure that investors have latest relevant information about the company and to inform the market so that the interest of the investors is safeguarded.<BR><BR>The reply is awaited.
5 months agoThe Exchange has sought clarification from Bafna Pharmaceuticals Ltd on March 23 2026 with reference to significant movement in price in order to ensure that investors have latest relevant information about the company and to inform the market so that the interest of the investors is safeguarded.<BR><BR>The reply is awaited.
5 months agoNewspaper Publication for the Unaudited Financial Results of the Company for the Quarter and Nine-Months ended December 31 2025 as published in "Business Standard" and "Makkal Kural" on February 13 2026.
6 months agoNewspaper Publication for the Unaudited Financial Results of the Company for the Quarter and Nine-Months ended December 31 2025 as published in "Business Standard" and "Makkal Kural" on February 13 2026.
6 months agoThe Board of Directors of the Company in their Meeting held on February 11 2026 has inter-alia considered and approved the Un-Audited Financial Results of the Company along with the Limited Review Report for the Quarter and Nine Months ended on December 31 2025.
6 months agoThe Board of Directors of the Company in the Meeting held on February 11 2026 has inter-alia considered and approved the Unaudited Financial Results of the Company along with the Limited Review Report issued by the Statutory Auditors for the Quarter and Nine-Months ended on December 31 2025.
6 months agoBafna Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2026 inter alia to consider and approve the Un-Audited Financial Results for the Quarter ended December 31 2025
7 months agoWe hereby inform you that the Outlook of the Credit Ratings assigned to the Bank loan facilites of the Company has been revised by ICRA Limited.
7 months agoCertificate under Regulation 74(5) of SEBI (DP) Regulations 2018 for the Quarter ended December 31 2025.
7 months agoAnnual reports
Concalls & investor presentations
No presentations found
Corporate Actions
Date
Type
Details
No data available.
Company details
Registered office
Bafna Towers New No 68, Old No.299 Thambu Chetty Street Chennai Tamil Nadu PIN: 600001 Tel No: 044- 25267517 / 25270992 / 42677555 Fax No: 044- 25231264 Email: [email protected] Internet: www.bafnapharma.com
Registrars
Subramanian Buildings No 1 , Club House Road,,Chennai Subramanian Buildings No 1 Club House Road NULL PIN: Tel No: 044-28460390/28460394 Fax No: 044-28460129 Email: NULL
Management
A Mohanachandran, Company Secretary & Compliance Officer
Shanmugam Hemalatha, Whole Time Director
Vinayak Dinesh Dendukuri, Whole Time Director - Quality
Akila Chintalapati Raju, Non Independent & Non Executive Director
Upendar Mekala Reddy, Non Independent & Non Executive Director
P K Sundaresan, Non Executive Independent Director
Ravichandran Chitra, Non Executive Independent Director
Details
BSE 532989
NSE BAFNAPH
ISIN INE878I01022